HER2-Positive Breast Cancer
Clinical research in human epidermal growth factor receptor 2-positive metastatic breast cancer, with interest in patients who have received prior HER2-directed treatment.
- HER2-positive metastatic breast cancer
- Previously treated disease
- Anti-tumor activity
The sponsor’s studies in this area focus on treatment options for advanced breast malignancies driven by HER2 expression.
Advanced HER2-Expressing Solid Tumors
Research extends beyond breast cancer to a broader set of HER2-expressing solid tumors, reflecting interest in tumor types defined by this molecular target.
- Advanced solid tumors
- HER2 expression
- Solid tumor oncology
These studies address advanced cancers with HER2-driven biology across multiple tumor settings.
Combination Immuno-Oncology
The sponsor investigates combinations that pair HER2-targeted therapy with immune checkpoint inhibition, including research involving nivolumab.
- Immune checkpoint inhibition
- Combination therapy
- Nivolumab-based regimens
This area reflects an interest in integrating targeted and immune-based approaches for solid tumor oncology.
Targeted Antibody Therapeutics
Research activity centers on antibody-based oncology therapeutics designed to engage HER2-positive malignancies.
- Monotherapy development
- Targeted biologics
- HER2-directed treatment strategies
These trials support investigation of biotherapeutic approaches in advanced cancer care.
